Scientific Index

Overview:This 14-day, multicenter, randomized, double-blind study investigated the efficacy and safety of a combination nasal spray containing azelastine (an antihistamine) and fluticasone (a corticosteroid) for patients with moderate-to-severe seasonal allergic...

OverviewThis systematic review and meta-analysis assessed the effectiveness of various combination therapies compared to monotherapies in treating allergic rhinitis (AR). The study analyzed data from 53 randomized controlled trials, focusing...

Overview:This study evaluated a novel triple spray composed of triamcinolone (a corticosteroid), azelastine (an antihistamine), and oxymetazoline (a decongestant) delivered in a single formulation. The goal was to determine whether...

OverviewThis Phase 2, double-blind, placebo-controlled clinical trial assessed the short-term efficacy and safety of combining mometasone furoate nasal spray (MFNS) with oxymetazoline (OXY) for the treatment of seasonal allergic rhinitis...

OverviewThis placebo-controlled trial assessed whether combining mometasone furoate (MFNS) and oxymetazoline (OXY) improves quality of life (QoL) in patients with seasonal allergic rhinitis (SAR). Subjects were randomized to one of...

OverviewThis randomized, double-blind, placebo-controlled, crossover study investigated whether intranasal fluticasone propionate can reverse oxymetazoline-induced tachyphylaxis (diminished decongestant response) and rebound congestion. Nineteen healthy volunteers were treated with oxymetazoline three times...

OverviewThis 60-week, randomized, double-blind clinical trial evaluated whether adding oxymetazoline (a topical decongestant) to intranasal corticosteroids (INS) could provide greater symptom relief in patients with chronic rhinitis compared to INS...

OverviewThis randomized controlled trial assessed the efficacy of combining oxymetazoline, a topical decongestant, with fluticasone furoate, an intranasal corticosteroid, in treating allergic rhinitis. Participants were assigned to receive either the...